<!DOCTYPE html><html lang="en">
<head>
<title>ObjectionResponses &lt; CTSpedia &lt; Foswiki</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1.5, user-scalable=yes" />
<meta name="mobile-web-app-capable" content="yes" />
<meta name="mobile-web-app-status-bar-style" content="black-translucent" />
<meta name="apple-mobile-web-app-capable" content="yes" />
<meta name="apple-mobile-web-app-status-bar-style" content="black-translucent" />
<link type="image/x-icon" rel="icon" href="../MISSING RESOURCE CTSpedia/ObjectionResponses/favicon.ico"> <link type="image/x-icon" href="../MISSING RESOURCE CTSpedia/ObjectionResponses/favicon.ico" rel="shortcut icon">
<link type="application/x-wiki" title="edit ObjectionResponses" href="ObjectionResponses.html" rel="alternate">
<meta name="description" content="ObjectionResponses" />
<link type="text/css" media="all" class="head SMILIESPLUGIN" rel="stylesheet" href="../System/SmiliesPlugin.attachments/smilies.css"><!--SMILIESPLUGIN-->
<script class="script JQUERYPLUGIN" src="../System/JQueryPlugin.attachments/jquery-2.2.4.js"></script><!--JQUERYPLUGIN-->
<script src="../System/JQueryPlugin.attachments/plugins/observer/observer.js?version=0.1" class="script JQUERYPLUGIN::OBSERVER"></script><!--JQUERYPLUGIN::OBSERVER-->
<script src="../System/JQueryPlugin.attachments/plugins/migrate/jquery.migrate.js?version=3.3.1" class="script JQUERYPLUGIN::MIGRATE"></script><!--JQUERYPLUGIN::MIGRATE-->
<script src="../System/JQueryPlugin.attachments/plugins/foswiki/jquery.foswiki.js?version=3.01" class="script JQUERYPLUGIN::FOSWIKI"></script><!--JQUERYPLUGIN::FOSWIKI-->
<script src="../System/JQueryPlugin.attachments/plugins/browser/jquery.browser.js?version=0.1.0" class="script JQUERYPLUGIN::BROWSER"></script><!--JQUERYPLUGIN::BROWSER-->
<script class='script JQUERYPLUGIN::FOSWIKI::PREFERENCES foswikiPreferences' type='text/json'>{
   "PUBURLPATH" : "/foswiki/pub",
   "USERNAME" : "WikiAdmin",
   "NAMEFILTER" : "[\\\\\\s*?~^$@%`\"'&|<:;>\\[\\]#\\x00-\\x1f]",
   "SCRIPTURLPATHS" : {},
   "WEB" : "CTSpedia",
   "SERVERTIME" : "08 Feb 2023 - 15:50",
   "TOPIC" : "ObjectionResponses",
   "USERSWEB" : "Main",
   "WIKIUSERNAME" : "Main.WikiAdmin",
   "SCRIPTSUFFIX" : "",
   "SCRIPTURLPATH" : "/foswiki/bin",
   "SKIN" : "natedit,pattern",
   "WIKINAME" : "WikiAdmin",
   "COOKIEREALM" : "",
   "PUBURL" : "http://biostat1478.dhcp.mc.vanderbilt.edu/foswiki/pub",
   "URLHOST" : "http://biostat1478.dhcp.mc.vanderbilt.edu",
   "SYSTEMWEB" : "System",
   "SCRIPTURL" : "http://biostat1478.dhcp.mc.vanderbilt.edu/foswiki/bin"
}
</script><!--JQUERYPLUGIN::FOSWIKI::PREFERENCES-->
</head>
<body>
<p align="left"> </p>
<h1 id="Comments_on_two_possible_objections">  Comments on two possible objections </h1>
My experience with peer reviews of previous related papers [1, 2], as well as published [3] and private correspondence about them, suggests that some readers may be quick to dismiss the case presented here because of perceived mistakes, poorly-thought-out counterarguments, or anticipated negative consequences of departures from current conventions. I comment here on two possible objections that seem particularly important, although this may only be a start on the objections that readers may formulate.
<p></p>
An initial reading of the threshold myth subsection may leave the impression that rejecting the myth depends on rejecting the established p-value threshold of 0.05, but this is not the case. I realize that the conventional p&lt;0.05 threshold is widely accepted (despite controversy [4-6]), and most researchers have seen situations where a completed study just misses this and the investigators believe that a few more subjects would have resulted in "success" (i.e., p&lt;0.05). This may seem like being on the wrong side of the threshold shown in Figure 1, but it does not imply that any threshold exists in a study's projected value when it is being planned. Indeed, a mathematical argument has previously shown that rigidly accepting the p=0.05 threshold leads to projected value being determined by power [1], which has the shape shown by the solid line, not the mythical dashed line. Acceptance of the p=0.05 threshold therefore <em>contradicts </em>the existence of a threshold in pre-study projected value.
<p></p>
The design-use mismatch underlies an argument frequently used to support a requirement for high power: that p&lt;0.05 in a study with low power is only weak evidence against the null hypothesis, because lower power implies that a higher proportion of p&lt;0.05 results are type I errors (the null hypothesis is actually true) [7, 8]. This argument relies on using only the information that p&lt;0.05, which would be a huge waste of a study's other information if we were really concerned with evidence about the issue being studied; only in an automatic decision-making context would we ignore estimates and exact p-values. Examining the actual p-value obtained produces a different picture--a given p-value from a larger study indicates <em>weaker </em>evidence against the null hypothesis than the same p-value from a smaller study [9]. In the pure automatic decision-making context, sample size does not influence the rate or consequences of type I errors [10]; only type II errors are affected, and the influence of sample size on projected value has diminishing marginal returns as illustrated in Figure 1 [1].
<p></p>
References
<p></p>
1. Bacchetti P, McCulloch CE, Segal MR: <strong>Simple, defensible sample sizes based on cost efficiency</strong>. <em>Biometrics </em>2008, <strong>64</strong>:577-585.
<p></p>
2. Bacchetti P, Wolf LE, Segal MR, McCulloch CE: <strong>Ethics and sample size</strong>. <em>American Journal of Epidemiology </em>2005, <strong>161</strong>:105-110.
<p></p>
3. Halpern SD, Karlawish JHT, Berlin JA: <strong>Re: "Ethics and sample size"</strong>. <em>American Journal of Epidemiology </em>2005, <strong>162</strong>:195-196.
<p></p>
4. Armstrong JS: <strong>Significance tests harm progress in forecasting</strong>. <em>Int J Forecast </em>2007, <strong>23</strong>:321-327.
<p></p>
5. Cohen J: <strong>The Earth is Round (p &lt; .05)</strong>. <em>American Psychologist </em>1994, <strong>49</strong>:997-1003.
<p></p>
6. Goodman SN: <strong>Toward evidence-based medical statistics. 1: The P value fallacy</strong>. <em>Annals of Internal Medicine </em>1999, <strong>130</strong>:995-1004.
<p></p>
7. O'Brien R: <strong>Webinar 4: Classical sample-size analysis for hypothesis testing (Part II)</strong>. <a href="http://www.biopharmnet.com/doc/doc03002-05.html">http://www.biopharmnet.com/doc/doc03002-05.html</a> 2009, accessed January 31, 2010.
<p></p>
8. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, <a class="foswikiNewLink" rel="nofollow" href="McPherson.html" title="Create this topic">McPherson</a> K, Peto J, Smith PG: <strong>Design and analysis of Randomized clinical-trials requiring prolonged observation of each patient .1. Introduction and design</strong>. <em>British Journal of Cancer </em>1976, <strong>34</strong>:585-612.
<p></p>
9. Royall RM: <strong>The effect of sample-size on the meaning of significance tests</strong>. <em>American Statistician </em>1986, <strong>40</strong>:313-315.
<p></p>
10. Bacchetti P, McCulloch CE, Segal MR: <strong>Simple, defensible sample sizes based on cost efficiency - Rejoinder</strong>. <em>Biometrics </em>2008, <strong>64</strong>:592-594.
<p></p>
-- <a title="Create this topic" rel="nofollow" class="foswikiNewLink" href="../Main/PeterBacchetti.html">PeterBacchetti</a> - 08 Jan 2012
<hr />
<p></p>
<hr />
<p></p>
</body>